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Background: An important potential clinical benefit of using capnography monitoring during procedural sedation and
analgesia (PSA) is that this technology could improve patient safety by reducing serious sedation-related adverse events,
such as death or permanent neurological disability, which are caused by inadequate oxygenation. The hypothesis is that
earlier identification of respiratory depression using capnography leads to a change in clinical management that prevents
hypoxaemia. As inadequate oxygenation/ventilation is the most common reason for injury associated with PSA, reducing
episodes of hypoxaemia would indicate that using capnography would be safer than relying on standard monitoring
alone.
Methods/design: The primary objective of this review is to determine whether using capnography during PSA in the
hospital setting improves patient safety by reducing the risk of hypoxaemia (defined as an arterial partial pressure of
oxygen below 60 mmHg or percentage of haemoglobin that is saturated with oxygen [SpO2] less than 90 %). A
secondary objective of this review is to determine whether changes in the clinical management of sedated patients
are the mediating factor for any observed impact of capnography monitoring on the rate of hypoxaemia. The potential
adverse effect of capnography monitoring that will be examined in this review is the rate of inadequate sedation.
Electronic databases will be searched for parallel, crossover and cluster randomised controlled trials comparing the use
of capnography with standard monitoring alone during PSA that is administered in the hospital setting. Studies that
included patients who received general or regional anaesthesia will be excluded from the review. Non-randomised
studies will be excluded. Screening, study selection and data extraction will be performed by two reviewers. The
Cochrane risk of bias tool will be used to assign a judgment about the degree of risk. Meta-analyses will be performed
if suitable.
Discussion: This review will synthesise the evidence on an important potential clinical benefit of capnography
monitoring during PSA within hospital settings.
Systematic review registration: PROSPERO CRD42015023740
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Description of the condition
Procedural sedation and analgesia (PSA) is used to con-
trol pain and distress during diagnostic and interven-
tional medical procedures. PSA is generally considered
to include the stages of moderate and deep sedation of
the continuum of anaesthesia [1]. Loss of consciousness
is not an intended outcome, and cardiac and respiratory
function may not be impaired with the doses and types
of sedative and analgesic medications used [1]. However,
PSA is still associated with at the least the same or po-
tentially even greater risk of serious sedation-related ad-
verse events, such as death or permanent neurological
disability, compared with general anaesthesia [2]. Due to
the potential that respiratory function may become im-
paired as a result of sedation-induced depression of the
central nervous system, frequent monitoring is recom-
mended [1, 3]. Respiratory function is usually evaluated
by observation of qualitative clinical signs (respiratory
rate, depth and effort) and oxygen saturation monitoring
[3]. Capnography is a respiratory monitoring device that
has become an accepted standard of care for PSA in
many circumstances. For example, the American Society
of Anesthesiology standards for Basic Anesthetic Moni-
toring require the use of capnography for both moderate
and deep sedation. In the UK, the Academy of Medical
Royal Colleges Standards and Guidance for Safe Sed-
ation Practice for Healthcare Procedures also include
capnography as a developmental standard for patients
receiving sedation where it has not already been imple-
mented into practice.
Description of the intervention
Capnography monitors use infrared spectroscopy to
measure the amount of carbon dioxide in exhaled breath
[4]. End-tidal carbon dioxide (ETCO2) is the partial
pressure of carbon dioxide measured at the end of exhal-
ation, which represents alveolar carbon dioxide concen-
tration [5]. Assuming that ventilation and perfusion is
normal, ETCO2 is approximately equal to the arterial
partial pressure of carbon dioxide [5]. A waveform track-
ing the level of carbon dioxide is displayed to show
changes in carbon dioxide concentration during the re-
spiratory cycle. Changes in ETCO2 values and/or the
shape of the capnography waveform may aid the diagno-
sis of iatrogenesis (e.g. ETT malplacement), physiological
abnormality (e.g. hyperventilation) or disease states [6].
Why is it important to do this review?
Hypoventilation or apnoea will theoretically precede hyp-
oxaemia if it is caused by sedation-induced respiratory de-
pression. For this reason, alterations in capnography
waveforms and ETCO2 levels that indicate hypoventilation
or apnoea should be early markers of sedation-inducedrespiratory depression. Clinical studies provide some evi-
dence to support this hypothesis. A meta-analysis revealed
that respiratory depression was 17.6 times more likely to
be detected among sedated patients who were monitored
with capnography than with standard monitoring alone
[7]. However, sedation-induced respiratory depression can
be transient, and not all episodes of respiratory depression
result in patient harm [8]. In this context, it is important to
note that intervening at the onset of an episode of respira-
tory depression that would have resolved spontaneously
without harming the patient may be counterproductive be-
cause it could result in inadequate sedation [9]. Rigorous
evaluation of the potential clinical benefits, including com-
prehensive syntheses of the available evidence, is therefore
required.
There are few systematic reviews available to inform
clinical practice and research regarding how to optimise
the clinical application of capnography during PSA. A
meta-analysis has been conducted to determine whether
capnography detected more respiratory complications
than standard monitoring alone [7]. Although it was
found in this systematic review that respiratory depres-
sion was more likely to be detected when capnography
was used during PSA, the clinical benefits arising from
increased detection were not examined [7]. A protocol
for a Cochrane systematic review that focuses on capno-
graphy during PSA has also been published [10]. How-
ever, this review will only include studies conducted in
the emergency department [10]. We searched the sys-
tematic review database, PROSPERO, on 27th April,
2014, with the terms capnography, end-tidal carbon di-
oxide and sedation. No other published or current sys-
tematic reviews were identified that focused on the use
of capnography during PSA.
One important potential clinical benefit of using cap-
nography monitoring during PSA is that this technology
could improve patient safety by reducing short-term ser-
ious sedation-related adverse events, such as death or
permanent neurological disability, which are caused by
inadequate oxygenation. The hypothesis is that earlier
identification of respiratory depression using capnography
leads to a change in clinical management that prevents
hypoxaemia. As inadequate oxygenation/ventilation is the
most common reason for injury associated with PSA, re-
ducing episodes of hypoxaemia would indicate that using
capnography would be safer than relying on standard
monitoring alone [11].
Objectives
The primary objective of this review is to determine
whether using capnography during PSA in the hospital
setting improves patient safety by reducing the risk of
hypoxaemia (defined as an arterial partial pressure of
oxygen below 60 mmHg or percentage of haemoglobin
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secondary objective of this review is to determine
whether changes in the clinical management of sedated
patients are the mediating factor for any observed im-
pact of capnography monitoring on the rate of hypox-
aemia. The potential adverse effect of capnography
monitoring that will be examined in this review is the
rate of inadequate sedation.
Methods/design
A systematic review and meta-analyses adhering to the
protocol outlined below will be conducted. Differences
between this protocol and the review will be reported.
Criteria for considering studies for this review
Types of studies
Parallel, crossover and cluster randomised controlled tri-
als will be included. Studies that tested non-inferiority
or equivalence hypotheses will not be included because
capnography monitoring is not used as a direct alterna-
tive for standard monitoring. Non-randomised or quasi-
randomised trials will not be included.
Types of clinical settings
Studies conducted in any hospital setting will be in-
cluded. Examples of hospital settings include emergency
departments, medical-imaging departments, endoscopy
suites and cardiac catheterisation laboratories. Dental
surgeries/clinics will be excluded due to the potentially
confounding influence of different staffing profiles (i.e.
the presence of a medical doctor versus a dentist).
Types of participants
Studies that included patients (adults or children) who
received procedural sedation and analgesia (defined as
administration of any intravenous sedative and/or anal-
gesic medications with or without local anaesthesia) will
be included in the review. Studies that included patients
who received general or regional anaesthesia will be ex-
cluded from the review.
Types of intervention
PSA was managed by a strategy where capnography
monitoring was used.
Types of comparison
PSA was managed without capnography monitoring.
Types of outcome measures
Primary outcome:
 Hypoxaemia (arterial partial pressure of oxygen
below 60 mmHg or percentage of haemoglobin that
is saturated with oxygen [SpO2] less than 90 % forany period of time). The definition for hypoxaemia
used in each included study will be extracted, as it is
possible that alternative definitions were used.
Secondary outcomes:
 Change in clinical managemento change in supplemental oxygen
o airway intervention (specific interventions used will
be extracted)
o medication titration (as a dichotomous variable)
o sedation reversal
o amount of sedative and analgesic medications used
(as a continuous variable with a separate analysis
undertaken for each medication) Unable to complete procedure as it was planned due
to inadequate sedation
 Sedation-related adverse events (death, neurological
deficits, unplanned conversion to general
anaesthesia/endotracheal intubation, unplanned
admission to intensive care unit)
As we hypothesise that changing clinicians’ clinical
management decision-making is the moderating mech-
anism for clinical benefits associated with capnography
monitoring during PSA, secondary outcomes will be the
amount of sedative and analgesic medication used and a
composite of whether there was a change in the use of
supplemental oxygen, use of an airway intervention or
administration of sedation reversal. We also hypothesise
that intervening at the onset of an episode of respiratory
depression that would have resolved spontaneously may
be counterproductive because it could result in inad-
equate sedation. For this reason, we will investigate the
number of procedures needing to be abandoned due to
inadequate sedation as a secondary outcome.
Search methods for identification of studies
Published, unpublished and ongoing studies will be iden-
tified by searching the following databases:
 The Cochrane Central Register of Controlled Trials
(CENTRAL) (1999 (established) to present);
 MEDLINE (OvidSP) (1966 to present);
 CINAHL (EBSCOhost) (1982 to present);
 ClinicalTrials.gov; and
 World Health Organization International Clinical
Trials Registry Platform.
Guidance from the Cochrane Handbook for System-
atic Reviews of Interventions, chapter 6.4, was used to
formulate the search strategy (Appendices 1, 2 and 3)
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study has been considered as potentially eligible based
on the abstract, attempts to either have the article trans-
lated or have the required data extracted will be made.Data collection and analysis
Selection of studies
measuresTitle and abstract screening will be performed
by two independent reviewers (AC and CD). Full-text
copies of all studies that appear to meet the inclusion
criteria will be obtained for further assessment. Second
screening will be performed by two independent reviewers
(AC and CD) applying all inclusion and exclusion criteria
(Additional file 1). Disagreement on eligibility will be re-
solved by discussion.Data extraction and management
AC and CD will independently extract data using the
data extraction form (Additional file 1). Differences of
opinion will be reconciled by mutual agreement. Data
will be entered into a database (Review Manager (RevMan),
version 5) for statistical analysis.Assessment of risk of bias in included studies
AC and CD will undertake the risk of bias assessment of
the included studies independently, as guided by the
Cochrane Handbook for Systematic Reviews of Inter-
ventions [12]. The Cochrane risk of bias tool will be used
to assign a judgment about the degree of risk (low risk of
bias, high risk of bias and unclear risk of bias) (Additional
file 1) [12].Measures of treatment effect
When the measure of the outcome is sufficiently consist-
ent across trials, we will use risk ratios for dichotomous
data and mean difference for continuous data with cor-
responding 95 % CIs.Unit/scale of analysis issues
The unit of analysis is based on the individual patient
(the unit that was randomised for comparison of inter-
ventions). We will use pre-crossover data for included
trials that used a crossover design. As per Cochrane
guidance, we will first assess whether data from cluster
randomised trials were analysed in a way that accounted
for clustering [13]. If not, trial results will be adjusted
for inclusion in a meta-analysis. Either an effective sam-
ple size will be calculated using the design effect to ad-
just the study data or the standard error of the estimated
intervention effect will be inflated by multiplying the
standard error by the square root of the design effect.Dealing with missing data from individuals
As the outcomes selected for this review are measured
during the procedure, it is unlikely that there will be
missing data. However, a potential reason for missing
data could be malfunction of monitoring equipment result-
ing in a loss of data about intra-procedural physio-
logical parameters. Therefore, we will attempt to perform
intention-to-treat (ITT) analyses wherever possible.
Assessment of heterogeneity
We will apply the chi-square test to check for evidence
of heterogeneity of intervention effects. In addition to
statistical assessments, variability in study participants,
interventions and outcomes will be examined qualita-
tively. We will use the I2 statistic to describe the per-
centage of total variation across studies that is due to
the heterogeneity rather than chance. An I2 value greater
than 50 % will be considered significant heterogeneity.
Visual inspection of the graphical representation of
study results with their 95 % CIs will also be used to as-
sess heterogeneity.
Assessment of publication bias
We will minimise the risk of publication bias by compre-
hensively searching databases and a clinical trial registry
[14]. We will attempt to obtain data from unpublished
work, and no language restriction will be imposed to re-
duce the risk of reporting bias. We will use a graphical
display (funnel plot if greater than ten studies are in-
cluded) of the size of treatment effect against the preci-
sion of the trial to investigate publication bias by looking
for signs of asymmetry. If there is asymmetry, we will
look for reasons other than publication bias.
Data synthesis
The appropriateness of undertaking meta-analysis in the
presence of significant clinical or statistical heterogeneity
will be considered. If appropriate, we will use the fixed-
effect model meta-analysis except where statistical het-
erogeneity is identified, in which case we will use the
random-effects model [12]. RevMan software (version 5)
will be used for meta-analyses. Results from individual
trials for the outcomes of this review will be tabulated
and synthesised in narrative form if meta-analyses can-
not be performed because the measure of the outcome
is not sufficiently consistent across trials.
Subgroup analysis
We will consider conducting subgroup analysis if the
data indicates clinical or statistical (I2 > 50 %) heterogen-
eity based on the following:
 age (adults or children);
 use of supplemental oxygen (used routinely or not);
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benzodiazepine, benzodiazepine and opioid
combination, ketamine, dexmedetomidine, other);
 whether an anaesthetist administered PSA (could
have been defined in this instance as monitored
anaesthesia care) or not;
 whether pre-specified respiratory depression criteria
were provided to guide clinicians’ decision-making;
and
 the type of procedure (diagnostic or interventional).
Summary of findings
We will present study findings in a standard “summary of
findings” (SoF) table, which will include the primary and
secondary outcomes, a measure of the typical burden of
these outcomes, the absolute and relative magnitude of ef-
fect, the numbers of participants and studies addressing
each outcome and a grade for the overall quality of the
body of evidence for each outcome. We will use the princi-
ples of the Grades of Recommendation, Assessment, Devel-
opment and Evaluation (GRADE) system [15] to assess the
quality of the body of evidence associated with the out-
comes and will construct the SoF table using GRADE soft-
ware. The GRADE approach appraises the quality of a
body of evidence according to the extent to which one can
be confident that an estimate of effect or association re-
flects the item being assessed. The quality of the body of
evidence considers within-study risk of bias (methodo-
logical quality), directness of the evidence, heterogeneity of
the data, precision of effect estimates and risk of publica-
tion bias.
Discussion
Results from this systematic review will be valuable for clin-
ical practice and research. To the best of our knowledge,
this systematic review will examine the current state of evi-
dence on the benefits to patient safety that may be associ-
ated with using capnography during PSA in the hospital
setting for the first time. Reducing the risk of the most
common antecedent event (hypoxia from inadequate oxy-
genation or ventilation) for sedation-related death and per-
manent neurological deficits would be a strong indicator
that capnography monitoring is likely to improve patient
safety during PSA. A synthesis of the existing evidence
will assist clinicians to integrate findings into their
practice. Gaps in the literature will be identified, which
need to be addressed in research to improve patient
safety during PSA.
Additional file
Additional file 1: Study eligibility, data extraction form, quality
assessment. The forms found in the file will be used by the reviewers in
the course of this systematic review.Appendices
Appendix 1. Search strategy for CENTRAL
#1 MeSH descriptor: [Capnography] explode all trees
#2 Capnograph*ab or end-tidal carbon dioxide:ti,ab
#3 #1 or #2
#4 MeSH descriptor: [Conscious Sedation] explode all
trees
#5 MeSH descriptor: [Deep Sedation] explode all trees
#6 #4 or #5
#7 #3 and #6
Appendix 2. MEDLINE (EBSCOHost) search strategy
1. exp Capnography/ or (capnograph*).mp. or end-tidal
carbon dioxide.mp.
2. Conscious Sedation/ or sedat*.ti,ab.
4. 1 and 2
Appendix 3. CINAHL (EBSCOhost) search strategy
S1 (MH “Capnography”) OR capnograph* or end-tidal
carbon dioxide
S2 AB (sedat* OR (MH “Propofol”) OR (MH “Conscious
Sedation”))
S4 S1 and S2
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